Background
Phase II single-arm study (ECOG E1308). N=80, p16-positive stage III–IV oropharyngeal SCC, ECOG PS 0–1. Low-risk: T1–T3, N0–N2c, M0; non-smoker or ≤10 pack-years. Enrolled 2009–2012. Induction chemotherapy to induce complete response, then de-intensified IMRT. Hypothesis: patients with CR after induction could receive 54 Gy (vs standard 70 Gy) with preserved efficacy and improved swallowing.
Interventions and follow up
Induction (all patients): Paclitaxel 200 mg/m² + carboplatin AUC6 + cetuximab 400→250 mg/m² q3wk × 3 cycles
Arm (≥PR responders, primary group): Cetuximab + IMRT 54 Gy/27 fx (de-intensified)
Arm (<PR or high-risk features): Cetuximab + IMRT 69.3 Gy
Primary endpoint: 2-year PFS in 54 Gy-treated group
mFollow up: 35.4 month
Arm (≥PR responders, primary group): Cetuximab + IMRT 54 Gy/27 fx (de-intensified)
Arm (<PR or high-risk features): Cetuximab + IMRT 69.3 Gy
Primary endpoint: 2-year PFS in 54 Gy-treated group
mFollow up: 35.4 month
Results
Response to induction: 56% cCR, 80% overall ≥PR
2-year PFS (54 Gy group): 80% (90% CI 66–93%)
2-year OS (54 Gy group): 94%
2-year PFS (69.3 Gy group): 70%
2-year PFS (54 Gy group): 80% (90% CI 66–93%)
2-year OS (54 Gy group): 94%
2-year PFS (69.3 Gy group): 70%
Adverse events
Induction grade 3–4: neutropenia 28%, fatigue 10%, sensory neuropathy 5%
IMRT 54 Gy: substantially reduced acute mucositis and dysphagia vs historical 70 Gy
Patient-reported (FACT-H&N, MDADI): significantly better swallowing scores in 54 Gy group
IMRT 54 Gy: substantially reduced acute mucositis and dysphagia vs historical 70 Gy
Patient-reported (FACT-H&N, MDADI): significantly better swallowing scores in 54 Gy group
Conclusions
Induction chemotherapy followed by de-escalated IMRT (54 Gy) + cetuximab yielded excellent 2-year PFS (80%) and OS (94%) in patients achieving ≥PR, with substantially improved swallowing and QOL. This concept-generating trial established feasibility of response-adaptive RT de-escalation in HPV+ OPC.
Key Limitations
Single arm, no randomized comparator — cannot conclude equivalence to standard 70 Gy CRT. Cetuximab used as sensitizer (subsequently shown inferior to cisplatin in HPV+ OPC by RTOG 1016/De-ESCALaTE), questioning regimen validity. CR-response selection enriches for favorable biology. Induction chemotherapy adds toxicity without proven OS benefit. PFS 80% below typical cisplatin+CRT outcomes (≥90% at 2 years).
Clinical Context
Provides proof of concept for response-adapted RT de-escalation but has not changed standard of care due to single-arm design and use of cetuximab. OPTIMA and others build on this framework with better induction regimens and ctDNA response assessment. The concept of treating clinical CRs with reduced-dose RT is being tested in PATHOS (UK) and MC1273. Standard remains 70 Gy + cisplatin-based CRT outside trials.
References